Journal ArticleDOI
Guidelines for the Management of Rheumatoid Arthritis 2002 Update
TLDR
The guideline reviewed in this month's column describes the recommended care of patients who have been previously diagnosed with RA.Abstract:
Rheumatoid arthritis (RA) is a progressive polyarthritis that is responsible for over nine million office visits annually. It is likely that most nurse practitioners will care for one or more patients with RA because approximately 1% of the adult population is affected by this disabling disorder. The guideline reviewed in this month's column describes the recommended care of patients who have been previously diagnosed with RA.read more
Citations
More filters
Journal ArticleDOI
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S Smolen,Robert Landewé,Ferdinand C. Breedveld,Maya H Buch,Maya H Buch,Gerd R Burmester,Maxime Dougados,Paul Emery,Paul Emery,Cécile Gaujoux-Viala,Laure Gossec,Jackie L Nam,Jackie L Nam,Sofia Ramiro,Kevin L. Winthrop,Maarten de Wit,Daniel Aletaha,Neil Betteridge,Johannes W. J. Bijlsma,Maarten Boers,Frank Buttgereit,Bernard Combe,Maurizio Cutolo,Nemanja Damjanov,Johanna M. W. Hazes,Marios Kouloumas,Tore K Kvien,Xavier Mariette,Karel Pavelka,Piet L. C. M. van Riel,Andrea Rubbert-Roth,Marieke Scholte-Voshaar,David Scott,T. Sokka-Isler,John B. Wong,Désirée van der Heijde +35 more
TL;DR: These recommendations intend informing rheumatologists, patients, national rheumology societies, hospital officials, social security agencies and regulators about EULAR's most recent consensus on the management of RA, aimed at attaining best outcomes with current therapies.
Journal ArticleDOI
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
Michael E. Weinblatt,Edward C. Keystone,Daniel E. Furst,Larry W. Moreland,Michael H. Weisman,C. Birbara,Leah A. Teoh,Steven A. Fischkoff,Elliot Chartash +8 more
TL;DR: The addition of adalimumab at a dosage of 20 mg, 40 mg, or 80 mg administered subcutaneously every other week to long-term MTX therapy in patients with active RA provided significant, rapid, and sustained improvement in disease activity over 24 weeks compared with MTX plus placebo.
Journal ArticleDOI
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
Lars Klareskog,Désirée van der Heijde,Julien P de Jager,A. K. S. Gough,Joachim R. Kalden,Michel Malaise,Emilio Martin Mola,Karel Pavelka,Jacques Sany,L. Settas,Joseph Wajdula,Ronald Pedersen,Saeed Fatenejad,Marie Sanda +13 more
TL;DR: The combination of etanercept and methotrexate was significantly better in reduction of disease activity, improvement of functional disability, and retardation of radiographic progression compared with methotRexate or etanorcept alone.
Journal ArticleDOI
American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Kenneth G. Saag,Gim Gee Teng,Nivedita M. Patkar,Jeremy Anuntiyo,Catherine Finney,Jeffrey R. Curtis,Harold E. Paulus,Amy S. Mudano,Maria Pisu,Mary Elkins-Melton,Ryan C. Outman,Jeroan J. Allison,Maria Suarez Almazor,S. Louis Bridges,W. Winn Chatham,Marc C. Hochberg,Catherine H. MacLean,Ted R. Mikuls,Larry W. Moreland,James O'Dell,Anthony M. Turkiewicz,Daniel E. Furst +21 more
TL;DR: Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient.
Journal ArticleDOI
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Josef S Smolen,Robert Landewé,Ferdinand C. Breedveld,Maxime Dougados,Paul Emery,Cécile Gaujoux-Viala,Cécile Gaujoux-Viala,Simone L Gorter,Rachel Knevel,Jackie L Nam,Monika Schoels,Daniel Aletaha,Maya H Buch,Laure Gossec,Tom W J Huizinga,Johannes W. J. Bijlsma,Gerd-Rüdiger Burmester,Bernard Combe,Maurizio Cutolo,Cem Gabay,Juan J. Gomez-Reino,Marios Kouloumas,Tore K Kvien,Emilio Martín-Mola,Iain B. McInnes,Karel Pavelka,Piet L. C. M. van Riel,M. Scholte,David Scott,Tuulikki Sokka,Guido Valesini,Ronald F van Vollenhoven,Kevin L. Winthrop,John H. Wong,Angela Zink,Désirée van der Heijde +35 more
TL;DR: In this article, the authors present a set of recommendations for the treatment of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids (GCs) that also account for strategic algorithms and deal with economic aspects.
References
More filters
Journal ArticleDOI
Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: comparison of low-dose cyclosporin and parenteral gold.
Henning Zeidler,T K Kvien,Pekka Hannonen,Frank A. Wollheim,Øystein Førre,H Geidel,Ingiäld Hafström,J P Kaltwasser,Marjatta Leirisalo-Repo,B. Manger,L Laasonen,E R Markert,H Prestele,P Kurki +13 more
TL;DR: Cyclosporin was comparable to parenteral gold in retarding progression of joint damage and was better tolerated in terms of adherence to therapy.
Journal ArticleDOI
Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment.
TL;DR: This study establishes that the combination of MTX and AZA in the dosages utilized is not associated with more toxicity than treatment with single agents; however, enhanced efficacy is also not seen.
Journal ArticleDOI
Interaction of cyclosporine A and nonsteroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis
TL;DR: The impairment of renal function when CYA and NSAID are combined is greater than that obtained with either agent alone, and appears to be, at least in part, due to renal vasoconstriction.
Journal ArticleDOI
Azathioprine in rheumatoid arthritis
TL;DR: During subsequent follow-up over a mean period of 40 months, 4 patients had discontinued therapy because of poor therapeutic response and 1 because of nausea, but Eleven of the 12 patients still taking azathioprine had maintained their initial beneficial response or showed further improvement.
Journal ArticleDOI
A randomized, double‐blind, 24‐week controlled study of low‐dose cyclosporine versus chloroquine for early rheumatoid arthritis
TL;DR: Both CSA and CQ are effective in alleviating the symptoms of active early RA and there is only slightly impaired renal function after 24 weeks of drug administration of either drug in patients with early RA.
Related Papers (5)
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
Frank C. Arnett,Steven M. Edworthy,Daniel A. Bloch,Dennis J. McShane,James F. Fries,Norman S. Cooper,L. A. Healey,Stephen R. Kaplan,Matthew H. Liang,Harvinder S. Luthra,Thomas A. Medsger,Donald M. Mitchell,David H. Neustadt,Robert S. Pinals,Jane G. Schaller,John T. Sharp,Ronald L. Wilder,Gene G. Hunder +17 more